The federal government’s decision in April to reclassify medical cannabis from Schedule I to Schedule III marks a significant policy shift, though the broader divide between federal and state marijuana law remains largely intact. The reclassification acknowledges an accepted healthcare use for cannabis, enabling medical marijuana businesses to claim some federal tax benefits and allowing new research at state universities. However, recreational marijuana remains a Schedule I drug federally, despite 24 states and the District of Columbia permitting recreational cannabis in various forms.
Tax changes and business uncertainty
Cannabis businesses have long been blocked from taking certain federal tax deductions due to Schedule I classification. “Going forward, we can be treated and taxed like a normal business, which ultimately helps the bottom line and allows us to reinvest more meaningfully in the states where we operate,” said Lauren Niehaus, executive director of government relations at Trulieve Cannabis Corp., one of the country’s largest cannabis companies operating dispensaries in eight states. However, the rescheduling also creates confusion. The reclassification carries federal registration requirements under the Controlled Substances Act that would require medical cannabis businesses to register with the DEA, pay annual fees, and comply with detailed reporting, inventory, and security rules that may overlap or conflict with existing state systems. In mid-May, the California Department of Cannabis Control proposed emergency regulations allowing businesses holding licenses for both medical and recreational marijuana to obtain separate licenses.
Research and public health concerns
Researchers say rescheduling could reduce longstanding barriers to studying cannabis’s medical use and safety. Chad Johnson, an assistant professor at the University of Maryland School of Pharmacy and director of the university’s medical cannabis graduate studies program, said rescheduling could allow academic institutions to study products already being sold in their states, making research more closely aligned with consumer use. However, some public health experts warn the change should not be interpreted as a signal that cannabis is risk-free. Dr. Alta DeRoo, chief medical officer of the Hazelden Betty Ford Foundation, cautioned: “It’s going to reduce the public’s perception of risk of cannabis, and right now, I don’t think the public is aware of the high potency that cannabis has.” New federal changes already face court challenges, with attorneys general from Indiana, Louisiana, and Nebraska filing a petition for review in the U.S. Court of Appeals.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://pagosadailypost.com/2026/06/02/hazy-outlook-as-feds-embrace-medical-marijuana/